AIMS: The purpose of this study was to investigate the functional role of G-protein-coupled inward rectifier potassium (GIRK) channels in the cardiac ventricle. METHODS AND RESULTS: Immunofluorescence experiments demonstrated that GIRK4 was localized in outer sarcolemmas and t-tubules in GIRK1 knockout (KO) mice, whereas GIRK4 labelling was not detected in GIRK4 KO mice. GIRK4 was localized in intercalated discs in rat ventricle, whereas it was expressed in intercalated discs and outer sarcolemmas in rat atrium. GIRK4 was localized in t-tubules and intercalated discs in human ventricular endocardium and epicardium, but absent in mid-myocardium. Electrophysiological recordings in rat ventricular tissue ex vivo showed that the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) and acetylcholine (ACh) shortened action potential duration (APD), and that the APD shortening was reversed by either the GIRK channel blocker tertiapin-Q, the adenosine A1 receptor antagonist DPCPX or by the muscarinic M2 receptor antagonist AF-DX 116. Tertiapin-Q prolonged APD in the absence of the exogenous receptor activation. Furthermore, CPA and ACh decreased the effective refractory period and the effect was reversed by either tertiapin-Q, DPCPX or AF-DX 116. Receptor activation also hyperpolarized the resting membrane potential, an effect that was reversed by tertiapin-Q. In contrast, tertiapin-Q depolarized the resting membrane potential in the absence of the exogenous receptor activation. CONCLUSION: Confocal microscopy shows that among species GIRK4 is differentially localized in the cardiac ventricle, and that it is heterogeneously expressed across human ventricular wall. Electrophysiological recordings reveal that GIRK current may contribute significantly to ventricular repolarization and thereby to cardiac electrical stability.
AIMS: The purpose of this study was to investigate the functional role of G-protein-coupled inward rectifier potassium (GIRK) channels in the cardiac ventricle. METHODS AND RESULTS: Immunofluorescence experiments demonstrated that GIRK4 was localized in outer sarcolemmas and t-tubules in GIRK1 knockout (KO) mice, whereas GIRK4 labelling was not detected in GIRK4 KO mice. GIRK4 was localized in intercalated discs in rat ventricle, whereas it was expressed in intercalated discs and outer sarcolemmas in rat atrium. GIRK4 was localized in t-tubules and intercalated discs in human ventricular endocardium and epicardium, but absent in mid-myocardium. Electrophysiological recordings in rat ventricular tissue ex vivo showed that the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) and acetylcholine (ACh) shortened action potential duration (APD), and that the APD shortening was reversed by either the GIRK channel blocker tertiapin-Q, the adenosine A1 receptor antagonist DPCPX or by the muscarinic M2 receptor antagonist AF-DX 116. Tertiapin-Q prolonged APD in the absence of the exogenous receptor activation. Furthermore, CPA and ACh decreased the effective refractory period and the effect was reversed by either tertiapin-Q, DPCPX or AF-DX 116. Receptor activation also hyperpolarized the resting membrane potential, an effect that was reversed by tertiapin-Q. In contrast, tertiapin-Q depolarized the resting membrane potential in the absence of the exogenous receptor activation. CONCLUSION: Confocal microscopy shows that among species GIRK4 is differentially localized in the cardiac ventricle, and that it is heterogeneously expressed across human ventricular wall. Electrophysiological recordings reveal that GIRK current may contribute significantly to ventricular repolarization and thereby to cardiac electrical stability.
Authors: H Dobrzynski; D D Marples; H Musa; T T Yamanushi; Z Henderson; Y Takagishi; H Honjo; I Kodama; M R Boyett Journal: J Histochem Cytochem Date: 2001-10 Impact factor: 2.479
Authors: D Dobrev; E Graf; E Wettwer; H M Himmel; O Hála; C Doerfel; T Christ; S Schüler; U Ravens Journal: Circulation Date: 2001-11-20 Impact factor: 29.690
Authors: D Brian Foster; Ting Liu; Kai Kammers; Robert O'Meally; Ni Yang; Kyriakos N Papanicolaou; C Conover Talbot; Robert N Cole; Brian O'Rourke Journal: J Proteome Res Date: 2016-08-03 Impact factor: 4.466
Authors: Allison Anderson; Baovi N Vo; Ezequiel Marron Fernandez de Velasco; Corey R Hopkins; C David Weaver; Kevin Wickman Journal: Mol Pharmacol Date: 2021-09-09 Impact factor: 4.436
Authors: Kanchan Kulkarni; Xueyi Xie; Ezequiel Marron Fernandez de Velasco; Allison Anderson; Kirill A Martemyanov; Kevin Wickman; Elena G Tolkacheva Journal: PLoS One Date: 2018-04-18 Impact factor: 3.240
Authors: Yu-Dong Fei; Mu Chen; Shuai Guo; Akira Ueoka; Zhenhui Chen; Michael Rubart-von der Lohe; Thomas H Everett; Zhilin Qu; James N Weiss; Peng-Sheng Chen Journal: Heart Rhythm Date: 2020-08-04 Impact factor: 6.343
Authors: Sarah Kammerer; Stephan Wenzel Jahn; Elke Winter; Sylvia Eidenhammer; Simin Rezania; Peter Regitnig; Martin Pichler; Wolfgang Schreibmayer; Thomas Bauernhofer Journal: J Clin Pathol Date: 2016-10-03 Impact factor: 3.411
Authors: Steven W Lee; Allison Anderson; Pilar A Guzman; Atsushi Nakano; Elena G Tolkacheva; Kevin Wickman Journal: Front Physiol Date: 2018-07-19 Impact factor: 4.566